N/A N=8 Utilization of the BIOWAVE Device to Treat Overactive Bladder
Overactive Bladder
Primary: Global Response Assessment (GRA) — 5.25; 4; 4.6; 5.1 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=104 Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011)
Acute Lymphoblastic Leukemia · Adult B Acute Lymphoblastic Leukemia · Childhood B Acute Lymphoblastic Leukemia
Primary: AALL08P1 Safety Outcome — 50.0 percentage of participants
Phase 4 N=50 Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose in Thai Children Primed With CD.JEVAX
Encephalitis
Primary: Change From Baseline in Geometric Mean Titers Against the Japanese Encephalitis Chimeric Virus at 28 Days Post Vaccination — 9144 titers
Phase 2 N=136 Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
Sarcoma
Primary: Progression Free Survival — 186; 271 Days
N/A N=50 Sinus Balloon Dilation in Pediatric Patients
Sinusitis
Primary: Technical Success: Sinuses Successfully Treated With Balloon Dilation — 157 sinus dilation attempts
N/A N=126 Adding Exercise to Antidepressant Medication Treatment for Depression
Depression
Primary: Percentage of Participants With Remission (Score of 12 or Less on Inventory for Depressive Symptomatology- Clinician-rated) — 18; 18 percentage of participants in…
Phase 3 N=957 Immunogenicity and Safety of Booster Dose of PoliorixTM Vaccine in Previously Vaccinated Toddlers
Poliomyelitis
Primary: Number of Subjects Seroprotected for Poliovirus Types 1, 2 and 3 Antibodies Above the Cut-off Value — 456; 456; 456 Participants
Phase 1 N=12 A Japanese Phase 1 Trial of c-Met Inhibitor MSC2156119J in Subjects With Solid Tumors
Solid Tumors
Primary: Number of Subjects Experiencing Dose Limiting Toxicity (DLT) — 0; 0; 0 subjects
Phase 3 N=769 A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Crohn's Disease · IBD · Colitis
Primary: Number of Participants With Clinical Response at Week 6 — 53; 84; 84 participants — p=0.002
Phase 3 N=89 Implantable Cardioverter-Defibrillator Use in the VA System
Cardiomyopathies
Primary: Referral for Implantable Cardioverter Defibrillator — 11; 1 participants
Phase 1 N=84 Safety and Tolerability Study of SHP626 in Overweight and Obese Adults
Non-Alcoholic Steatohepatitis
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Standard Hematology — 0; 0; 0; 0 participants
Phase 2 N=354 A 28-Day Parallel Group Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
COPD
Primary: Change From Baseline in Trough FEV1 (Forced Expiratory Volume in One Second) — -32.4; 19.4; 155.0; 134.2 mL
Phase 3 N=300 A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes
Diabetes Mellitus, Type 2
Primary: Change From Baseline to 28 Weeks in Hemoglobin A1c (HbA1c) — -1.44; -0.67 percentage of change — p=<.001
N/A N=482 The Use of Apneic Oxygenation During Prolonged Intubation in Pediatric Patients: a Randomized Clinical Trial
Intubation of Pediatric Dental Surgery Patients
Primary: Time of Oxygen Saturation Change — 30; 67; 75 seconds
Phase 2 N=103 Ixabepilone + Carboplatin Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Objective Response Rate (ORR) — 30.4; 34 percentage of participants